Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer

BACKGROUND: Despite the advent of improved therapeutic options for advanced prostate cancer, the durability of clinical benefits is limited due to inevitable development of resistance. By constitutively sustaining androgen receptor (AR) signaling, expression of ligand-binding domain truncated AR var...

Descripción completa

Detalles Bibliográficos
Autores principales: Hung, Chiu-Lien, Liu, Hao-Hsuan, Fu, Chih-Wei, Yeh, Hsun-Hao, Hu, Tsan-Lin, Kuo, Zong-Keng, Lin, Yu-Chin, Jhang, Mei-Ru, Hwang, Chrong-Shiong, Hsu, Hung-Chih, Kung, Hsing-Jien, Wang, Ling-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011747/
https://www.ncbi.nlm.nih.gov/pubmed/36893587
http://dx.doi.org/10.1016/j.ebiom.2023.104500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011747/
https://www.ncbi.nlm.nih.gov/pubmed/36893587
http://dx.doi.org/10.1016/j.ebiom.2023.104500

Ejemplares similares